Recent attention has focused on the hereditary basis of pancreatic ductal adenocarcinoma (PDAC), a fatal cancer with an overall 5-year survival of 8%.1 For inherited cancer syndromes such as Lynch and hereditary breast and ovarian cancer syndromes, research in the last 20 or more years has culminated in strategies for clinical management, with tailored screening, prophylactic surgery, and targeted therapies aimed at reducing the risk of cancer development or treating cancer in high-risk individuals and their family members. Strategies for identification and management of Lynch syndrome and hereditary breast and ovarian cancer syndrome have been formalized in several clinical guidelines that have been adopted by the medical community.
Syngal S, Furniss CS. Germline Genetic Testing for Pancreatic Ductal Adenocarcinoma at Time of Diagnosis. JAMA. 2018;319(23):2383–2385. doi:10.1001/jama.2018.6227
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: